PMID- 23278171
OWN - NLM
STAT- MEDLINE
DCOM- 20140224
LR  - 20130724
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 79
IP  - 3
DP  - 2013 Sep
TI  - Low normal free T4 confers decreased high-density lipoprotein antioxidative 
      functionality in the context of hyperglycaemia.
PG  - 416-23
LID - 10.1111/cen.12138 [doi]
AB  - OBJECTIVES: Low normal thyroid function may promote the development of 
      atherosclerotic cardiovascular disease by thus far poorly defined mechanisms. We 
      tested the impact of thyroid function on HDL antioxidative capacity, a metric of 
      its antiatherogenic functionality, in euthyroid subjects with varying degrees of 
      glucose tolerance. DESIGN AND SUBJECTS: Seventy subjects with Type 2 diabetes 
      mellitus (T2DM), 37 subjects with impaired fasting glucose (IFG) and 31 subjects 
      with normal fasting glucose (NFG) (revised NCEP-ATPIII criteria) participated in 
      a cross-sectional study. MEASUREMENTS: HDL antioxidative capacity (standardized 
      for HDL cholesterol) was measured as the percentage inhibition of low-density 
      lipoprotein oxidation in vitro. RESULTS: TSH, free T4 and HDL antioxidative 
      capacity were not different among NFG, IFG and T2DM subjects (P > 0.25 for each). 
      HDL antioxidative capacity was correlated positively with free T4 (r = 0.320, P = 
      0.007), and negatively with plasma glucose (r = -0.394, P < 0.001) in T2DM only. 
      Taking account of age and sex, the relationship of HDL antioxidative 
      functionality with free T4 was modified by glucose tolerance status (P = 0.040 
      and P = 0.008 for interactions of IFG and T2DM with free T4 respectively). 
      Prevailing plasma glucose also interacted positively with free T4 on HDL 
      antioxidative capacity (P = 0.054). CONCLUSIONS: In the context of chronic 
      hyperglycaemia, low free T4 within the euthyroid range confers diminished HDL 
      antioxidative capacity, a pathophysiologically relevant metric of HDL 
      functionality.
CI  - (c) 2012 John Wiley & Sons Ltd.
FAU - Triolo, Michela
AU  - Triolo M
AD  - Department of Endocrinology, University Medical Center Groningen and University 
      of Groningen, Groningen, The Netherlands.
FAU - de Boer, Jan Freark
AU  - de Boer JF
FAU - Annema, Wijtske
AU  - Annema W
FAU - Kwakernaak, Arjan J
AU  - Kwakernaak AJ
FAU - Tietge, Uwe J F
AU  - Tietge UJ
FAU - Dullaart, Robin P F
AU  - Dullaart RP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130511
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Antioxidants)
RN  - 0 (Blood Glucose)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Thyroid Hormones)
RN  - Q51BO43MG4 (Thyroxine)
SB  - IM
MH  - Aged
MH  - Antioxidants/*metabolism
MH  - Atherosclerosis/metabolism
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/blood
MH  - Female
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Hyperglycemia/*blood/drug therapy
MH  - Lipoproteins, HDL/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress
MH  - Regression Analysis
MH  - Thyroid Hormones/blood
MH  - Thyroxine/*blood
EDAT- 2013/01/03 06:00
MHDA- 2014/02/25 06:00
CRDT- 2013/01/03 06:00
PHST- 2012/11/23 00:00 [received]
PHST- 2012/12/06 00:00 [revised]
PHST- 2012/12/13 00:00 [revised]
PHST- 2012/12/21 00:00 [accepted]
PHST- 2013/01/03 06:00 [entrez]
PHST- 2013/01/03 06:00 [pubmed]
PHST- 2014/02/25 06:00 [medline]
AID - 10.1111/cen.12138 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2013 Sep;79(3):416-23. doi: 10.1111/cen.12138. Epub 2013 
      May 11.